Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

ons contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.VIVUS, Inc.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited)Three Months EndedMarch 31March 3120112010Operating expenses:Research and development$
4,480$
,211General and administrative5,4285,164Total operating expenses9,90815,375Loss from operations(9,908)(15,375)Interest and other income (expense), net

42(1,233)Loss from continuing operations before income taxes(9,866)(16,608)Provision for income taxes(1)(1)Net loss from cont
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Bythewood, South Carolina (PRWEB) April 17, 2015 ... solutions and steam system services, released their newly ... 2015. The customer facing website effectively promotes ... proposition. , All the information that a ... training, steam system services, company capabilities, industries serviced, ...
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)...  Schulman Associates IRB, Inc., the industry-leading central IRB ... lease on Laboratory Drive in the heart of ... location will house review board and service staff, which ... and customer service to clients. CBRE ... the deal, while Capital Associates Management, LLC represented the ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
... April 30 Interleukin,Genetics, Inc. (Amex: ILI ... M.,Lurier, CPA, as its Chief Financial Officer., ... Genetics, Inc.,commented on the appointment, "Eliot is an ... spirit and a proven,record of achievement in managing ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, today announced that Prof. Frans M.J.,Debruyne, M.D., ... Institutes,in The Netherlands, won the award for Best ... Annual European Association of Urology Meeting, which,was held ...
... Viral Load Assay, ORANGE COUNTY, Calif., April ... ) announced today that it has licensed certain,rights ... from Siemens Healthcare,Diagnostics. Under the agreement, Beckman Coulter ... HCV blood test for use on the company,s,molecular ...
Cached Biology Technology:Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer 2Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6Beckman Coulter Acquires Rights to Hepatitis C Virus 2
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... physical world. That,s a fact cancer researchers are beginning to ... mathematics in their efforts to understand how cancer develops -- ... researchers at the University of Michigan Comprehensive Cancer Center, has ... of the top cancer research journals and a new grant ...
... once discussed only in scientific or eco-centric circles, has ... sustainability remains elusive. On Friday, scholars and legal ... address how to meet mankind,s present needs without compromising ... The Environmental & Energy Law & Policy Journal,s fifth ...
... chemicals from plant material could produce liquid fuel for just ... the infrastructure is set up in the right way, states ... Bioproducts & Biorefining . Developed by scientists at the ... as bioliq, and is able to produce a range of ...
Cached Biology News:Physics, math provide clues to unraveling cancer 2Symposium at UH will address how to put 'sustainability' into practice 2Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon) 2
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... HT is available as a ...
... a modified cap analog in which the ... replaced with OCH3. Because of this substitution, ... with the remaining hydroxyl group thus forcing ... a result, unlike transcripts synthesized with conventional ...
...
Biology Products: